Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations

We will evaluate the bioavailability of naproxen 500 mg administered as three dfferent formulations...

Date First Received: April 23, 2008

Last Updated: June 9, 2008

Verified by: Pozen, June 2008

Clinical Trial Phase: Phase 1 | Start Date: March 2008

Overall Status: Completed

Estimated Enrollment: 30

Brief Summary

Official Title: “An Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Naproxen 500 mg Administered as PN 400 (Naproxen / Esomeprazole), as the [Active Comparator 1], or as [Active Comparator 2] in Healthy Volunteers”

Condition Keyword(s):

We will evaluate the bioavailability of naproxen 500 mg administered as three dfferent formulations.

Study Type: Interventional

Study Design: Basic Science, Randomized, Open Label, Uncontrolled, Crossover Assignment, Bio-equivalence Study

Study Primary Completion Date: June 2008

Intervention(s) in this Clinical Trial

  • Drug: PN400
    • naproxen 500 mg /esomeprazole 20 mg
  • Drug: naproxen
    • naproxen 500 mg tablet
  • Drug: naproxen
    • naproxen 500 mg

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: A
    • PN400 (naproxen/esomeprazole)
  • Active Comparator: B
    • naproxen 500 mg
  • Active Comparator: C
    • naproxen 500 mg

Outcome Measures for this Clinical Trial

Primary Measures

  • To assess and compare the pharmacokinetics and relative bioavailability of a single oral dose of naproxen 500 mg administered in 3 formulations
    • Time Frame: 72-hour PK
      Safety Issue?: No

Secondary Measures

  • To evaluate the safety of the 3 treatments
    • Time Frame: entire study duration
      Safety Issue?: Yes

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Healthy male or non-pregnant female subjects between 18-55 years of age as well as other standard inclusion criteria for a study of this nature

Exclusion Criteria:

  • Standard exclusion criteria for a study of this nature

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 55 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Clinical Trial Sponsor Information

Lead Sponsor: Pozen

Additional Information

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00665743

Study ID Number: PN400-102

ClinicalTrials.gov Identifier: NCT00665743

Health Authority: United States: Food and Drug Administration

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.